探讨肺表面活性物质联合辅助通气治疗新生儿肺透明膜病的疗效  

Efficacy of pulmonary surfactant combined with assisted ventilation in the treatment of neonatal hyaline membrane disease

作　　者：陈淑珍 CHEN Shu-zhen(Xinhui District Maternal and Child Health Hospital,Jiangmen 529100,China)

机构地区：[1]江门市新会区妇幼保健院,529100

出　　处：《中国现代药物应用》2025年第4期111-114,共4页Chinese Journal of Modern Drug Application

摘　　要：目的探讨肺表面活性物质联合辅助通气治疗新生儿肺透明膜病的疗效。方法以300例新生儿肺透明膜病患儿为研究对象,凭借随机数字表法分为对照组及观察组,每组150例。对照组应用辅助通气治疗,观察组应用肺表面活性物质联合辅助通气治疗。对比两组临床疗效,肺功能指标[最大呼气流量(PEF)、第1秒用力呼气容积(FEV1)、第1秒用力呼气容积占用力肺活量的比例(FEV1/FVC)、用力肺活量(FVC)],血气分析指标[pH、氧合指数(OI)、动脉血二氧化碳分压(PaCO_(2))、动脉血氧分压(PaO_(2))]。结果治疗后,观察组总有效率99.33%高于对照组的93.33%(P<0.05)。治疗后,观察组PEF、FEV1、FEV1/FVC、FVC分别为(5.19±0.52)L/s、(2.04±0.18)L、(76.12±5.88)%、(2.68±0.23)L,均高于对照组的(4.57±0.43)L/s、(1.55±0.12)L、(68.28±4.93)%、(2.27±0.18)L(P<0.05)。治疗前,两组pH、OI、PaCO_(2)、PaO_(2)对比,无统计学意义(P>0.05);治疗后,观察组pH(7.36±0.16)、OI(352.19±72.26)mm Hg(1 mm Hg=0.133 kPa)、PaO_(2)(85.29±7.2)mm Hg高于对照组的(7.21±0.13)、(308.39±73.11)mm Hg、(80.39±6.98)mm Hg,PaCO_(2)(38.39±3.21)mm Hg低于对照组的(45.29±4.11)mm Hg(P<0.05)。结论新生儿肺透明膜病接受肺表面活性物质联合辅助通气治疗疗效显著,患儿的肺功能以及血气分析指标明显改善,临床应用价值显著。Objective To explore the efficacy of pulmonary surfactant combined with assisted ventilation in the treatment of neonatal hyaline membrane disease.Methods A total of 300 cases of neonatal hyaline membrane disease were selected for the study and divided into a control group and an observation group according to random numerical table,each with 150 cases.The control group was treated with assisted ventilation,while the observation group was treated with pulmonary surfactant combined with assisted ventilation.Comparison was made on clinical efficacy,pulmonary function indexes[peak expiratory flow rate(PEF),forced expiratory volume in one second(FEV1),the ratio of FEV1 to forced vital capacity(FEV1/FVC),FVC],and blood gas analysis indicators[pH,oxygenation index(OI),arterial partial pressure of carbon dioxide(PaCO_(2)),arterial partial pressure of oxygen(PaO_(2))]between the two groups.Results After treatment,the total effective rate of 99.33%in the observation group was higher than 93.33%in the control group(P<0.05).After treatment,PEF,FEV1,FEV1/FVC and FVC in the observation group were(5.19±0.52)L/s,(2.04±0.18)L,(76.12±5.88)%and(2.68±0.23)L,which were higher than(4.57±0.43)L/s,(1.55±0.12)L,(68.28±4.93)%and(2.27±0.18)L in the control group(P<0.05).Before treatment,there was no statistical significance in pH,OI,PaCO_(2)and PaO_(2)between the two groups(P>0.05).After treatment,the observation group had pH of(7.36±0.16),OI of(352.19±72.26)mm Hg(1 mm Hg=0.133 kPa)and PaO_(2)of(85.29±7.2)mm Hg,which were higher than(7.21±0.13),(308.39±73.11)mm Hg and(80.39±6.98)mm Hg in the control group;the observation group had lower PaCO_(2)of(38.39±3.21)mm Hg than(45.29±4.11)mm Hg in the control group(P<0.05).Conclusion The efficacy of pulmonary surfactant combined with assisted ventilation in treating neonatal hyaline membrane disease is remarkable,and the pulmonary function and blood gas analysis indicators of the neonates improved significantly,which is of great clinical value.

关 键 词：肺表面活性物质 辅助通气 新生儿肺透明膜病 临床效果 

分 类 号：R56[医药卫生—呼吸系统]